Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03772028 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Study acronym: OVHIPEC-2
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Apr 1, 2025 to Apr 1, 2028 Trial status: Recruiting to Active, Not Recruiting · Completion date: Apr 1, 2026 to Dec 1, 2028 · Site details revised at 28 of 28 sitesv10 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Apr 1, 2026 to Dec 1, 2028
    • Site details revised at 28 of 28 sites
  2. Study sites: 21 to 28v9
  3. Re-verified, no change to tracked fieldsv8
  4. Study sites: 19 to 21v7
  5. Primary completion date: Apr 1, 2024 to Apr 1, 2025 Study sites: 13 to 19 · Completion date: Apr 1, 2025 to Apr 1, 2026v6 Show 2 more changesShow less
    • Study sites: 13 to 19
    • Completion date: Apr 1, 2025 to Apr 1, 2026
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 1 to 13v5
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Nov 1, 2019 to Jan 1, 2020v4 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 1, 2019 to Jan 1, 2020
  3. Start date: Apr 1, 2019 to Nov 1, 2019v3
  4. Start date: Feb 1, 2019 to Apr 1, 2019 Primary completion date: Feb 1, 2024 to Apr 1, 2024 · Completion date: Feb 1, 2025 to Apr 1, 2025 · Study title expanded, about 1 wordv2 Show 3 more changesShow less
    • Primary completion date: Feb 1, 2024 to Apr 1, 2024
    • Completion date: Feb 1, 2025 to Apr 1, 2025
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
Trial Details
NCT Number NCT03772028
Lead Sponsor The Netherlands Cancer Institute
Conditions Ovarian Cancer
Enrollment 538 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov